Skip to main content

Array BioPharma reports updated results

Array BioPharma Inc. (Nasdaq: ARRY) reported positive updated results from a Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, binimetinib and cetuximab sending the stock price up $2.42 to close at $15.56.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.